Anzeige
Erschienen in:
01.02.2008 | Cornea
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2008
Einloggen, um Zugang zu erhaltenAbstract
Background
To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. Design: interventional case series involving five patients (age: 42 ± 14 years).
Methods
Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 ± 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).
Results
Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 ± 28%; 13–75%).
Conclusions
Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.